Michael Borrie Selected Research

Alzheimer Disease (Alzheimer's Disease)

12/2021	Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab.
6/2020	The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score.
10/2019	The Use of Random Forests to Classify Amyloid Brain PET.
1/2018	Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
1/2015	A hybrid manifold learning algorithm for the diagnosis and prognostication of Alzheimer's disease.
1/2015	Donepezil improves gait performance in older adults with mild Alzheimer's disease: a phase II clinical trial.
1/2013	Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.
2/2009	Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer's disease.
7/2006	Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia.
3/2004	A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Borrie Research Topics

Disease

10	Alzheimer Disease (Alzheimer's Disease) 12/2021 - 03/2004
5	Cognitive Dysfunction 01/2021 - 01/2015
4	Dementia (Dementias) 12/2020 - 07/2006
2	Leukoencephalopathies 06/2020 - 10/2019
2	Lacunar Stroke 06/2020 - 10/2019
2	Transient Ischemic Attack 06/2020 - 10/2019
1	Vascular Diseases (Vascular Disease) 11/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021
1	Cerebrovascular Trauma 11/2021
1	Brain Edema (Cerebral Edema) 01/2018
1	Frontotemporal Dementia (Semantic Dementia) 01/2015
1	Disease Progression 02/2009
1	Amyloid Plaque 02/2009
1	Atrophy 02/2009
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 07/2006

Drug/Important Bio-Agent (IBA)

3	florbetapirIBA 06/2020 - 01/2018
2	Monoclonal AntibodiesIBA 12/2021 - 01/2013
2	Amyloid beta-PeptidesIBA 12/2021 - 01/2018
2	Apolipoproteins E (ApoE)IBA 01/2021 - 02/2009
2	Nootropic Agents (Nootropics)IBA 01/2015 - 02/2009
1	aducanumabIBA 12/2021
1	Hemoglobins (Hemoglobin)IBA 11/2021
1	CholesterolIBA 11/2021
1	Glucose (Dextrose)FDA LinkGeneric 11/2021
1	Biomarkers (Surrogate Marker)IBA 11/2021
1	ApolipoproteinsIBA 01/2021
1	solanezumabIBA 01/2018
1	Amyloid (Amyloid Fibrils)IBA 01/2018
1	Oxytocin (Pitocin)FDA LinkGeneric 01/2015
1	Donepezil (Aricept)FDA LinkGeneric 01/2015
1	Biological ProductsIBA 01/2015
1	ponezumabIBA 01/2013
1	Memantine (Namenda)FDA Link 07/2006
1	Doxycycline (Periostat)FDA LinkGeneric 03/2004
1	Rifampin (Rifampicin)FDA LinkGeneric 03/2004

Therapy/Procedure

2	Therapeutics 12/2021 - 07/2006
1	Long-Term Care 12/2020